` Comparison: 012790 vs AZN - Alpha Spread

S
012790
vs
AZN

Over the past 12 months, Sinil Pharmaceutical Co Ltd has underperformed AZN, delivering a return of -1% compared to the AZN's +30% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
012790
AZN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

Sinil Pharmaceutical Co Ltd Intrinsic Value
HIDDEN
Show
AZN Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
S
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
6 320 KRW
AstraZeneca PLC
LSE:AZN
15 506 GBX
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
012790, AZN

012790
AZN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
S
Sinil Pharmaceutical Co Ltd
Revenue
AstraZeneca PLC
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
012790, AZN

012790
AZN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
S
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
AstraZeneca PLC
LSE:AZN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Sinil Pharmaceutical Co Ltd
45.1%
AZN
81.3%

Operating Margin

Sinil Pharmaceutical Co Ltd
14.7%
AZN
23.9%

Net Margin

Sinil Pharmaceutical Co Ltd
14%
AZN
17.4%

FCF Margin

Sinil Pharmaceutical Co Ltd
11.8%
AZN
14.8%

ROE

Sinil Pharmaceutical Co Ltd
7.7%
AZN
22.9%

ROA

Sinil Pharmaceutical Co Ltd
6.8%
AZN
9.4%

ROIC

Sinil Pharmaceutical Co Ltd
8.2%
AZN
13%

ROCE

Sinil Pharmaceutical Co Ltd
7.9%
AZN
17.6%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
012790, AZN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
012790, AZN

Performance Gap Between 012790 and AZN
HIDDEN
Show

Performance By Year
012790, AZN

Loading
012790
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 012790 to other stocks
LLY
Eli Lilly and Co
More expensive
vs Sinil Pharmaceutical Co Ltd
JNJ
Johnson & Johnson
More expensive
vs Sinil Pharmaceutical Co Ltd
ROG
Roche Holding AG
Cheaper
vs Sinil Pharmaceutical Co Ltd
NOVN
Novartis AG
More expensive
vs Sinil Pharmaceutical Co Ltd
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett